Axon Enterprise (NASDAQ:AXON) Price Target Raised to $600.00 at Needham & Company LLC

by · The Cerbat Gem

Axon Enterprise (NASDAQ:AXON – Get Free Report) had its price objective hoisted by research analysts at Needham & Company LLC from $525.00 to $600.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target would indicate a potential downside of 1.22% from the company’s current price.

AXON has been the subject of several other reports. The Goldman Sachs Group upped their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Barclays increased their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. JMP Securities increased their price target on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a report on Thursday, October 31st. Bank of America initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $398.62.

View Our Latest Research Report on AXON

Axon Enterprise Trading Up 29.6 %

NASDAQ:AXON traded up $138.64 during trading hours on Friday, hitting $607.39. The company had a trading volume of 2,928,070 shares, compared to its average volume of 533,687. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company has a 50-day moving average of $409.39 and a 200 day moving average of $344.81. The company has a market cap of $45.90 billion, a P/E ratio of 160.26, a P/E/G ratio of 11.70 and a beta of 0.94. Axon Enterprise has a 1 year low of $212.88 and a 1 year high of $610.93.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s quarterly revenue was up 34.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.80 EPS. Sell-side analysts expect that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the sale, the director now owns 7,379 shares of the company’s stock, valued at approximately $2,752,588.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Axon Enterprise news, Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $400.00, for a total value of $44,000.00. Following the transaction, the director now directly owns 1,934 shares in the company, valued at approximately $773,600. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the completion of the transaction, the director now owns 7,379 shares in the company, valued at $2,752,588.37. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 369,172 shares of company stock valued at $136,270,842. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of institutional investors have recently modified their holdings of AXON. Mirae Asset Global Investments Co. Ltd. raised its holdings in Axon Enterprise by 2.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,434 shares of the biotechnology company’s stock worth $3,825,000 after purchasing an additional 301 shares during the last quarter. Empirical Finance LLC lifted its position in Axon Enterprise by 11.2% during the first quarter. Empirical Finance LLC now owns 1,023 shares of the biotechnology company’s stock worth $320,000 after buying an additional 103 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Axon Enterprise by 11.8% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,468 shares of the biotechnology company’s stock worth $1,398,000 after purchasing an additional 471 shares during the period. Empowered Funds LLC purchased a new position in shares of Axon Enterprise in the 1st quarter worth about $340,000. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Axon Enterprise by 5.1% during the 1st quarter. Oppenheimer & Co. Inc. now owns 3,802 shares of the biotechnology company’s stock valued at $1,190,000 after buying an additional 183 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Featured Stories